Mexidol

ID: mexidol

Aliases: ethylmethylhydroxypyridine succinate, emoxypine succinate

Type: compound

Route/form: oral or route depends on studied product

Status: approved_in_some_countries

Evidence level: mechanistic

Best data tier: direct mechanistic; adjacent early human

Support scope: human, non-human/mechanistic, review/regulatory

Source types: human_trial, mechanistic, review

Linked sources: 4

Broad outcomes: Brain / mood / sleep, Longevity / mitochondrial / redox

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• antioxidant claims
• membrane effects
• anti-ischemic claims

Optimization domains

• neuroprotection
• anxiety
• ischemia

Research basis

• Mexidol has regional clinical and mechanistic literature, so it belongs as a neurovascular/metabolic antioxidant-adjunct entry rather than a pure anecdote.
• Human disease-context studies and recent mechanism reviews explain why it appears in brain-function and anxiety-adjacent discussions.
• The useful frame is regional-drug evidence mapping, not assuming Western-label-level proof.

Limits, risks, and missing evidence

• High-quality replicated Western trial anchors and label-level context are limited.
• Mechanistic breadth can become a non-falsifiable antioxidant narrative.
• Drug-transporter and polypharmacy issues should be considered rather than treating it as a benign supplement.

Risk flags

• regional drug
• evidence generalizability
• polypharmacy uncertainty

Linked papers, labels, and reviews

1. Known and new ideas about Mexidol mechanism of action
   review / pubmed_mexidol_review_2025
   Recent mechanism review; mostly regional literature.
2. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia
   review / pubmed_mexidol_chronic_ischemia_2020
   Russian-language clinical review for Mexidol in chronic cerebral ischemia; clinical context differs from broad nootropic claims.
3. The assessment of the clinical efficacy, vasoactive and metabolic effects of mexidol in elderly patients with discirculatory encephalopathy
   human_trial / pubmed_mexidol_encephalopathy_rct_2012
   Small randomized clinical study in elderly patients with chronic cerebral ischemia/discirculatory encephalopathy; not evidence for healthy cognitive enhancement.
4. Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1
   mechanistic / pubmed_mexidol_transporter_2023
   Transporter-interaction study; useful for mechanism and drug-interaction hypotheses, not efficacy.